基于“肾精-骨代谢”理论的桃红四物汤通过调控RANKL/OPG轴改善糖尿病性骨质疏松的多靶点协同机制
DOI:
作者:
作者单位:

作者简介:

通讯作者:

基金项目:

河北省中医药管理局课题项目(2022425)


Taohong Siwu Tang improves diabetes induced osteoporosis by regulating RANKL/OPG axis based on the theory of “kidney essence-bone metabolism
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
    摘要:

    目的 基于“肾精-骨代谢”理论,探讨桃红四物汤通过调控核因子κB受体激活因子配体(RANKL)/骨保护素(OPG)信号通路改善糖尿病性骨质疏松症(DOP)的机制,并分析其多靶点协同作用。方法 选取60只SPF级SD大鼠,12只设为空白组,其余建立DOP模型并随机分为模型组和桃红四物汤治疗(低、中、高剂量)组,每组12只。低、中、高剂量组分别给予相应剂量的桃红四物汤灌胃,空白组和模型组灌服等体积生理盐水,持续12周。通过ELISA检测血清中骨代谢标志物[碱性磷酸酶(ALP)、骨钙素(OCN)、抗酒石酸酸性磷酸酶(TRAP)]和炎症因子(TNF-α、IL-6)水平;TUNEL染色检测骨组织细胞凋亡率;Western blot和qPCR测定骨组织中RANKL和OPG的蛋白及mRNA表达水平。通过体外细胞实验验证RANKL/OPG通路的关键性。结果 与模型组相比,桃红四物汤治疗组大鼠的ALP、OCN和TRAP水平显著改善,TNF-α和IL-6水平降低(均P<0.05);TUNEL染色显示骨组织细胞凋亡率降低(P<0.05);Western blot和qPCR结果表明,RANKL的蛋白和mRNA表达降低,OPG的蛋白和mRNA表达升高(均P<0.05),且高剂量组效果最为显著(P<0.01)。体外实验显示,RANKL诱导显著增加了TRAP+细胞数,提高了RANKL蛋白表达,降低了OPG蛋白表达,增加了RANKL/OPG比值(均P<0.05);而桃红四物汤干预显著减少了TRAP+细胞数,降低了RANKL蛋白表达,提高了OPG蛋白表达,降低了RANKL/OPG比值(均P<0.01)。OPG过表达显著提高了ALP活性、Runx2和OCN mRNA表达(均P<0.05),而OPG过表达联合桃红四物汤组的ALP活性、Runx2和OCN mRNA表达均显著高于OPG过表达组(均P<0.01)。结论 桃红四物汤通过调控RANKL/OPG信号通路,降低炎症因子表达和细胞凋亡,显著改善DOP大鼠的骨代谢,其作用机制与多靶点协同效应密切相关

    Abstract:

    Objective Based on the theory of “kidney essence-bone metabolism”, to explore the mechanism of Taohong Siwu Tang in improving diabetes induced osteoporosis(DOP) by regulating RANKL/OPG signal pathway, and analyze its multi target synergy.Methods 60 SPF grade SD rats were selected, with 12 as the blank group. The remaining rats were used to establish a DOP model and randomly divided into a model group and low, medium, and high-dose treatment groups with Taohong Siwu Tang, with 12 rats in each group. The treatment group was given corresponding doses of Taohong Siwu Tang by gavage, while the blank group and model group were given equal volumes of physiological saline by gavage for 12 weeks. Detect the levels of bone metabolism markers (ALP, OCN, TRAP) and inflammatory factors (TNF-α, IL-6) in serum by ELISA. TUNEL staining was used to detect the apoptosis rate of bone tissue cells. Western blot and qPCR were used to measure the protein and mRNA expression levels of RANKL and OPG in bone tissue. The criticality of the RANKL/OPG pathway through in vitro cell experiments were verified.Results Compared with the model group, the treatment group with Taohong Siwu Tang significantly improved the levels of ALP, OCN, and TRAP in rats (P<0.05), while the levels of TNF-α and IL-6 decreased (P<0.05). TUNEL staining showed a decrease in apoptosis rate of bone tissue cells; Western blot and qPCR results showed that the protein and mRNA expression of RANKL decreased (P<0.05), while the protein and mRNA expression of OPG increased (P<0.05), with the high-dose group showing the most significant effect (P<0.01). In vitro experiments showed that RANKL induction significantly increased the number of TRAP+cells, increased RANKL protein expression, decreased OPG protein expression, and increased the RANKL/OPG ratio(P<0.05). The intervention of Taohong Siwu Tang significantly reduced the number of TRAP+cells, decreased the expression of RANKL protein, increased the expression of OPG protein, and reduced the RANKL/OPG ratio(P<0.01). Overexpression of OPG significantly increased ALP activity, Runx2, and OCN mRNA expression(P<0.05), while the combination of OPG overexpression and Taohong Siwu Tang group showed significantly higher ALP activity, Runx2, and OCN mRNA expression than the OPG overexpression group(P<0.01).Conclusion Taohong Siwu Tang significantly improves bone metabolism in DOP rats by regulating the RANKL/OPG signaling pathway, reducing the expression of inflammatory factors and cell apoptosis. Its mechanism of action is closely related to multi-target synergistic effects

    参考文献
    相似文献
    引证文献
引用本文

赵国秀,魏芯芯,蓝青,等.基于“肾精骨代谢”理论的桃红四物汤通过调控RANKL/OPG轴改善糖尿病性骨质疏松的多靶点协同机制[J].西部医学,2025,37(10):1425-1430,1437.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2025-10-20
您是第位访问者
网站版权所有:《西部医学》编辑部     蜀ICP备18038379号-4
地址:四川省成都市武侯区小天竺街75号财富国际18F-1号    邮政编码:610041
电话:028-85570072/85588403 本网站支持 IPv6    E-mail:xbyxqk@163.com
技术支持:北京勤云科技发展有限公司